Therapeutic Potential of Myricetin in the Treatment of Neurological, Neuropsychiatric, and Neurodegenerative Disorders
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Myricetin (MC), 3,5,7,3',4',5'-hexahydroxyflavone, chemically belongs to a flavonoid category known to confer antioxidant, antimicrobial, antidiabetic, and neuroprotective effects. MC is known to suppress the generation of Reactive Oxygen Species (ROS), lipid peroxidation (MDA), and inflammatory markers. It has been reported to improve insulin function in the human brain and periphery. Besides this, it modulates several neurochemicals including glutamate, GABA, serotonin, etc. MC has been shown to reduce the expression of the enzyme Mono Amine Oxidase (MAO), which is responsible for the metabolism of monoamines. MC treatment reduces levels of plasma corticosterone and restores hippocampal BDNF (full form) protein in stressed animals. Further, MC has shown its protective effect against amyloid-beta, MPTP, rotenone, 6-OHDA, etc. suggesting its potential role against neurodegenerative disorders. The aim of the present review is to highlight the therapeutic potential of MC in the treatment of several neurological, neuropsychiatric, and neurodegenerative disorders.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
CNS & neurological disorders drug targets - (2023) vom: 18. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar Sethiya, Neeraj [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer’s |
|---|
| Anmerkungen: |
Date Revised 18.07.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/1871527322666230718105358 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359619134 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359619134 | ||
| 003 | DE-627 | ||
| 005 | 20231226081249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871527322666230718105358 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM359619134 | ||
| 035 | |a (NLM)37461364 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumar Sethiya, Neeraj |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic Potential of Myricetin in the Treatment of Neurological, Neuropsychiatric, and Neurodegenerative Disorders |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Myricetin (MC), 3,5,7,3',4',5'-hexahydroxyflavone, chemically belongs to a flavonoid category known to confer antioxidant, antimicrobial, antidiabetic, and neuroprotective effects. MC is known to suppress the generation of Reactive Oxygen Species (ROS), lipid peroxidation (MDA), and inflammatory markers. It has been reported to improve insulin function in the human brain and periphery. Besides this, it modulates several neurochemicals including glutamate, GABA, serotonin, etc. MC has been shown to reduce the expression of the enzyme Mono Amine Oxidase (MAO), which is responsible for the metabolism of monoamines. MC treatment reduces levels of plasma corticosterone and restores hippocampal BDNF (full form) protein in stressed animals. Further, MC has shown its protective effect against amyloid-beta, MPTP, rotenone, 6-OHDA, etc. suggesting its potential role against neurodegenerative disorders. The aim of the present review is to highlight the therapeutic potential of MC in the treatment of several neurological, neuropsychiatric, and neurodegenerative disorders | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alzheimer’s | |
| 650 | 4 | |a Anxiety | |
| 650 | 4 | |a Depression | |
| 650 | 4 | |a Huntington’s Disease. | |
| 650 | 4 | |a Myricetin | |
| 650 | 4 | |a Parkinson’s | |
| 650 | 4 | |a Stroke | |
| 650 | 4 | |a disease | |
| 700 | 1 | |a Ghiloria, Neha |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastav, Akanksha |e verfasserin |4 aut | |
| 700 | 1 | |a Bisht, Dheeraj |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar Chaudhary, Sushil |e verfasserin |4 aut | |
| 700 | 1 | |a Walia, Vaibhav |e verfasserin |4 aut | |
| 700 | 1 | |a Sabir Alam, Md |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS & neurological disorders drug targets |d 2006 |g (2023) vom: 18. Juli |w (DE-627)NLM161975518 |x 1996-3181 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:18 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871527322666230718105358 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 18 |c 07 | ||